This article will help you read and understand your pathology report for endometrioid borderline tumour of the ovary.
by Emily Goebel, MD FRCPC, updated on July 27, 2019
The ovaries are part of the female reproductive tract. They are small organs that are attached to the uterus by the fallopian tubes. The outer surface of the ovaries are lined by a thin layer of specialized tissue called an epithelium that forms a barrier around the outside of the ovary.
The organs inside the abdomen are lined by a thin layer of tissue called the peritoneum that is made up of similar cells. The ovaries also contain large cells called eggs. The tissue below the epithelium is called stroma.
Endometrioid borderline tumours are tumours of low malignant potential which means that they have a small risk of turning into cancer. The behaviour of a borderline tumour is in between that of an endometrioid cystadenofibroma which is a non-cancerous tumour and endometrioid adenocarcinoma which is a type of cancer.
Endometrioid borderline tumours can start either on the outer surface of the ovary or within tissue below the surface of the ovary.
In many cases, patients with endometrioid borderline tumours have a history of endometriosis or their ovaries will show evidence of endometriosis. For this reason, it is believed that in some women, endometriosis acts as the ‘seed’ for the development of endometrioid borderline tumours or endometrioid adenocarcinoma in the future. However, the vast majority of women who have endometriosis will never develop endometrioid borderline tumours or endometrioid adenocarcinoma, so the risk associated with endometriosis is still quite low.
Under the microscope these tumours are made up of crowded glands lined by abnormal cells. The cells in an endometrioid borderline tumour look similar to the cells that normally line the endometrial cavity of the uterus which is why they are called endometrioid (meaning “like” the endometrium).
Your pathologist will carefully examine the tumour for single tumour cells or irregular glands that have moved out of the epithelium and into the stroma below. The movement of tumour cells into the stroma is called invasion and tumours with this feature are called endometrioid borderline tumours with microinvasion.
Microinvasion is important because it is associated with a higher risk of recurrence and worse prognosis. If this feature is seen it will be described in your report.
For most women, the diagnosis of endometrioid borderline tumour is only made when the entire tumour has been surgically removed and sent to a pathologist for examination. The fallopian tube and uterus may be removed at the same time.
In some situations, the surgeon will request an intraoperative or frozen section consultation from your pathologist. The diagnosis made by your pathologist during the intraoperative consultation can change the type of surgery performed or the treatment offered after the surgery is completed.
All ovarian tumours are examined to see if there are any holes or tears in the outer surface of the tumour or ovary. The outer surface is referred to as the capsule. The capsule is described as intact if no holes or tears are identified. The capsule is described as ruptured if the outer surface contains any large holes or tears.
This information is important because a capsule that ruptures inside the body may spill tumour cells into the abdominal cavity. A ruptured capsule is associated with worse prognosis and is used to determine the tumour stage (see Pathologic stage below).
Your pathologist will carefully examine the tissue under the microscope to see if there are any tumour cells on the surface of the ovary.
Tumour cells on the surface of the ovary increase the risk that the tumour will spread to other organs in the pelvis or abdomen. It is also used to determine the tumour stage (see Pathologic stage below).
Small samples of tissue may be removed in a procedure called a biopsy to see if tumour cells have spread to the pelvis or abdomen. These biopsies which are often called omentum or peritoneum are sent for pathological examination along with the tumour.
Other organs (such as bladder, small intestine, or large intestine) are not typically removed and sent for pathological examination unless they are directly attached to the tumour. In these cases your pathologist will examine each organ under the microscope to see if there are any tumour cells attached to those organs.
Tumour cells in other organs are used to determine the tumour stage (see Pathologic stage below).
Lymph nodes are small immune organs located throughout the body. Tumour cells can travel from the tumour to a lymph node through lymphatic channels located in and around the tumour (see Lymphovascular invasion above). The movement of tumour cells from the tumour to a lymph node is called a metastasis.
Your pathologist will carefully examine all lymph nodes for tumour cells. Lymph nodes that contain tumour cells are often called positive while those that do not contain any tumour cells are called negative. Most reports include the total number of lymph nodes examined and the number, if any, that contain tumour cells.
Since the risk of lymph node involvement is low for endometrioid borderline tumours, in many cases lymph nodes are not removed at the time of surgery.
The pathologic stage for endometrioid borderline tumour is based on the TNM staging system, an internationally recognized system originally created by the American Joint Committee on Cancer.
This system uses information about the primary tumour (T), lymph nodes (N), and distant metastatic disease (M) to determine the complete pathologic stage (pTNM). Your pathologist will examine the tissue submitted and give each part a number. In general, a higher number means more advanced disease and worse prognosis.
Endometrioid borderline tumour is given a metastatic stage of 0 or 1 based on the presence of tumour cells at a distant site in the body (for example the lungs). The metastatic stage can only be determined if tissue from a distant site is sent for pathological examination.